A Novel Role for the RNA-Binding Protein FXR1P in Myoblasts Cell-Cycle Progression by Modulating p21/Cdkn1a/Cip1/Waf1 mRNA Stability

PLoS Genetics

Volumn 9, Issue 3, 2013, Pages

  Davidovic, Laetitia ^a,b   Durand, Nelly ^a,b   Khalfallah, Olfa ^a,b   Tabet, Ricardo ^c   Barbry, Pascal ^a,b   Mari, Bernard ^a,b   Sacconi, Sabrina ^d   Moine, Hervé ^c   Bardoni, Barbara ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ISOPROTEIN; MESSENGER RNA; PROTEIN P21; RNA BINDING PROTEIN; RNA BINDING PROTEIN FXR1P; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE PROGRESSION; CELL LINE; COMPLEX FORMATION; CONTROLLED STUDY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE EXPRESSION PROFILING; HALF LIFE TIME; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MOLECULAR PATHOLOGY; MUSCLE DEVELOPMENT; MYOBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RNA BINDING; REGULATORY MECHANISM; RNA STABILITY; UPREGULATION;

ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; MICE; MUSCLE DEVELOPMENT; MUSCULAR DYSTROPHIES; MYOBLASTS; RNA STABILITY; RNA, MESSENGER; RNA-BINDING PROTEINS;

ANURA; DANIO RERIO; MUS;

EID: 84876011845     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003367     Document Type: Article

References (65)

1. Khandjian EW, (1999) Biology of the fragile X mental retardation protein, an RNA-binding protein. Biochem Cell Biol 77: 331-342.
2. Sutherland GR, (1977) Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science 197: 265-266.
3. Coy JF, Sedlacek Z, Bachner D, Hameister H, Joos S, et al. (1995) Highly conserved 3′ UTR and expression pattern of FXR1 points to a divergent gene regulation of FXR1 and FMR1. Hum Mol Genet 4: 2209-2218.
4. Zhang Y, O'Connor JP, Siomi MC, Srinivasan S, Dutra A, et al. (1995) The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. Embo J 14: 5358-5366.
5. Penagarikano O, Mulle JG, Warren ST, (2007) The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet 8: 109-129.
6. Kirkpatrick LL, McIlwain KA, Nelson DL, (1999) Alternative splicing in the murine and human FXR1 genes. Genomics 59: 193-202.
7. Dubé M, Huot ME, Khandjian EW, (2000) Muscle specific fragile X related protein 1 isoforms are sequestered in the nucleus of undifferentiated myoblast. BMC Genet 1: 4.
8. Khandjian EW, Bardoni B, Corbin F, Sittler A, Giroux S, et al. (1998) Novel isoforms of the fragile X related protein FXR1P are expressed during myogenesis. Hum Mol Genet 7: 2121-2128.
9. Davidovic L, Sacconi S, Bechara EG, Delplace S, Allegra M, et al. (2008) Alteration of expression of muscle specific isoforms of the fragile X related protein 1 (FXR1P) in facioscapulohumeral muscular dystrophy patients. J Med Genet 45: 679-685.
10. Davidovic L, Huot ME, Khandjian EW, (2005) Lost once, the Fragile X Mental Retardation protein is now back onto brain polyribosomes. RNA Biol 2: 1-3.
11. Bakker CE, de Diego Otero Y, Bontekoe C, Raghoe P, Luteijn T, et al. (2000) Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse. Exp Cell Res 258: 162-170.
12. Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, et al. (2008) Expanded CTG repeats within the DMPK 3′ UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A 105: 2646-2651.
13. Mientjes EJ, Willemsen R, Kirkpatrick LL, Nieuwenhuizen IM, Hoogeveen-Westerveld M, et al. (2004) Fxr1 knockout mice show a striated muscle phenotype: implications for Fxr1p function in vivo. Hum Mol Genet 13: 1291-1302.
14. Huot ME, Bisson N, Davidovic L, Mazroui R, Labelle Y, et al. (2005) The RNA-binding protein fragile X-related 1 regulates somite formation in Xenopus laevis. Mol Biol Cell 16: 4350-4361.
15. Van't Padje S, Chaudhry B, Severijnen LA, van der Linde HC, Mientjes EJ, et al. (2009) Reduction in fragile X related 1 protein causes cardiomyopathy and muscular dystrophy in zebrafish. J Exp Biol 212: 2564-2570.
16. Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G, (1993) The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74: 291-298.
17. Tamanini F, Bontekoe C, Bakker CE, van Unen L, Anar B, et al. (1999) Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations. Hum Mol Genet 8: 863-869.
18. Khandjian EW, Bechara E, Davidovic L, Bardoni B, (2005) Fragile X Mental Retardation Protein: many partners and multiple targets for a promisuous function. Current Genomics 6: 515-522.
19. Garnon J, Lachance C, Di Marco S, Hel Z, Marion D, et al. (2005) Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. J Biol Chem 280: 5750-5763.
20. Vasudevan S, Steitz JA, (2007) AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell 128: 1105-1118.
21. Bechara E, Davidovic L, Melko M, Bensaid M, Tremblay S, et al. (2007) Fragile X related protein 1 isoforms differentially modulate the affinity of fragile X mental retardation protein for G-quartet RNA structure. Nucleic Acids Res 35: 299-306.
22. Whitman SA, Cover C, Yu L, Nelson DL, Zarnescu DC, et al. (2011) Desmoplakin and talin2 are novel mRNA targets of fragile X-related protein-1 in cardiac muscle. Circ Res 109: 262-271.
23. Montarras D, Pinset C, Chelly J, Kahn A, Gros F, (1989) Expression of MyoD1 coincides with terminal differentiation in determined but inducible muscle cells. EMBO J 8: 2203-2207.
24. Watson PA, Hanauske-Abel HH, Flint A, Lalande M, (1991) Mimosine reversibly arrests cell cycle progression at the G1-S phase border. Cytometry 12: 242-246.
25. Gong J, Traganos F, Darzynkiewicz Z, (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218: 314-319.
26. Kreipe H, Heidebrecht HJ, Hansen S, Rohlk W, Kubbies M, et al. (1993) A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 142: 3-9.
27. Buckingham M, (1994) Muscle differentiation. Which myogenic factors make muscle? Curr Biol 4: 61-63.
28. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, et al. (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267: 1018-1021.
29. Sabourin LA, Rudnicki MA, (2000) The molecular regulation of myogenesis. Clin Genet 57: 16-25.
30. van der Giessen K, Di-Marco S, Clair E, Gallouzi IE, (2003) RNAi-mediated HuR depletion leads to the inhibition of muscle cell differentiation. J Biol Chem 278: 47119-47128.
31. Schaeffer C, Bardoni B, Mandel JL, Ehresmann B, Ehresmann C, et al. (2001) The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. Embo J 20: 4803-4813.
32. Ule J, Jensen K, Mele A, Darnell RB, (2005) CLIP: a method for identifying protein-RNA interaction sites in living cells. Methods 37: 376-386.
33. Kikin O, D'Antonio L, Bagga PS, (2006) QGRS Mapper: a web-based server for predicting G-quadruplexes in nucleotide sequences. Nucleic Acids Res 34: W676-682.
34. Yamane A, Amano O, Slavkin HC, (2003) Insulin-like growth factors, hepatocyte growth factor and transforming growth factor-alpha in mouse tongue myogenesis. Dev Growth Differ 45: 1-6.
35. Philippou A, Maridaki M, Halapas A, Koutsilieris M, (2007) The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 21: 45-54.
36. Gruber AR, Fallmann J, Kratochvill F, Kovarik P, Hofacker IL, (2011) AREsite: a database for the comprehensive investigation of AU-rich elements. Nucleic Acids Res 39: D66-69.
37. Puri PL, Balsano C, Burgio VL, Chirillo P, Natoli G, et al. (1997) MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes. Oncogene 14: 1171-1184.
38. Polesskaya A, Rudnicki MA, (2002) A MyoD-dependent differentiation checkpoint: ensuring genome integrity. Dev Cell 3: 757-758.
39. Tamanini F, Kirkpatrick LL, Schonkeren J, van Unen L, Bontekoe C, et al. (2000) The fragile X-related proteins FXR1P and FXR2P contain a functional nucleolar-targeting signal equivalent to the HIV-1 regulatory proteins. Hum Mol Genet 9: 1487-1493.
40. Castets M, Schaeffer C, Bechara E, Schenck A, Khandjian EW, et al. (2005) FMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts. Hum Mol Genet 14: 835-844.
41. Kwan KY, Lam MM, Johnson MB, Dube U, Shim S, et al. (2012) Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex. Cell 149: 899-911.
42. Subramanian M, Rage F, Tabet R, Flatter E, Mandel JL, et al. (2011) G-quadruplex RNA structure as a signal for neurite mRNA targeting. EMBO Rep 12: 697-704.
43. Melko M, Bardoni B, (2010) The role of G-quadruplex in RNA metabolism: involvement of FMRP and FMR2P. Biochimie 92: 919-926.
44. Kikin O, Zappala Z, D'Antonio L, Bagga PS, (2008) GRSDB2 and GRS_UTRdb: databases of quadruplex forming G-rich sequences in pre-mRNAs and mRNAs. Nucleic Acids Res 36: D141-148.
45. Arhin GK, Boots M, Bagga PS, Milcarek C, Wilusz J, (2002) Downstream sequence elements with different affinities for the hnRNP H/H′ protein influence the processing efficiency of mammalian polyadenylation signals. Nucleic Acids Res 30: 1842-1850.
46. Danckwardt S, Kaufmann I, Gentzel M, Foerstner KU, Gantzert AS, et al. (2007) Splicing factors stimulate polyadenylation via USEs at non-canonical 3′ end formation signals. EMBO J 26: 2658-2669.
47. Gagnon KT, Corey DR, (2012) Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression. Nucleic Acid Ther 22: 3-16.
48. Mortensen RD, Serra M, Steitz JA, Vasudevan S, (2011) Posttranscriptional activation of gene expression in Xenopus laevis oocytes by microRNA-protein complexes (microRNPs). Proc Natl Acad Sci U S A 108: 8281-8286.
49. Caudy AA, Myers M, Hannon GJ, Hammond SM, (2002) Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev 16: 2491-2496.
50. Ishizuka A, Siomi MC, Siomi H, (2002) A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev 16: 2497-2508.
51. Chi SW, Zang JB, Mele A, Darnell RB, (2009) Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460: 479-86.
52. Cho SJ, Zhang J, Chen X, (2010) RNPC1 modulates the RNA-binding activity of, and cooperates with, HuR to regulate p21 mRNA stability. Nucleic Acids Res 38: 2256-2267.
53. Briata P, Forcales SV, Ponassi M, Corte G, Chen CY, et al. (2005) p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol Cell 20: 891-903.
54. Waggoner SA, Johannes GJ, Liebhaber SA, (2009) Depletion of the poly(C)-binding proteins alphaCP1 and alphaCP2 from K562 cells leads to p53-independent induction of cyclin-dependent kinase inhibitor (CDKN1A) and G1 arrest. J Biol Chem 284: 9039-9049.
55. Scoumanne A, Cho SJ, Zhang J, Chen X, (2011) The cyclin-dependent kinase inhibitor p21 is regulated by RNA-binding protein PCBP4 via mRNA stability. Nucleic Acids Res 39: 213-224.
56. Kitzmann M, Fernandez A, (2001) Crosstalk between cell cycle regulators and the myogenic factor MyoD in skeletal myoblasts. Cell Mol Life Sci 58: 571-579.
57. Guo K, Wang J, Andres V, Smith RC, Walsh K, (1995) MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol 15: 3823-3829.
58. Winokur ST, Barrett K, Martin JH, Forrester JR, Simon M, et al. (2003) Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord 13: 322-333.
59. Osborne RJ, Welle S, Venance SL, Thornton CA, Tawil R, (2007) Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology 68: 569-577.
60. Hawke TJ, Meeson AP, Jiang N, Graham S, Hutcheson K, et al. (2003) p21 is essential for normal myogenic progenitor cell function in regenerating skeletal muscle. Am J Physiol Cell Physiol 285: C1019-1027.
61. Yaffe D, Saxel O, (1977) A myogenic cell line with altered serum requirements for differentiation. Differentiation 7: 159-166.
62. Blau HM, Pavlath GK, Hardeman EC, Chiu CP, Silberstein L, et al. (1985) Plasticity of the differentiated state. Science 230: 758-766.
63. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
64. Davidovic L, Bechara E, Gravel M, Jaglin XH, Tremblay S, et al. (2006) The nuclear microspherule protein 58 is a novel RNA-binding protein that interacts with fragile X mental retardation protein in polyribosomal mRNPs from neurons. Hum Mol Genet 15: 1525-1538.
65. Davidovic L, Navratil V, Bonaccorso CM, Catania MV, Bardoni B, et al. (2011) A metabolomic and systems biology perspective on the brain of the Fragile X syndrome mouse model. Genome Res 21: 2190-2202.